David S. Shames

Center for Global Development — United States

Medicine · Health Sciences

65h-index19.1kcitations311works14.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(123), Cancer Genomics and Diagnostics(71), Cancer Immunotherapy and Biomarkers(66), RNA modifications and cancer(56), Lung Cancer Research Studies(49)

Publications309 total

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
Nature Communications·2025· 2 citedOpen Access
2790P Machine learning classification of small cell lung cancer using plasma multiomics in IMPower133
Annals of Oncology·2025
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials
Journal of Thoracic Oncology·2025· 3 cited
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
Journal of Clinical Investigation·2025· 2 citedOpen Access
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer
Nature Communications·2025· 10 citedOpen Access
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
Abstract 6404: NOTCH1 drives immunogenicity through STING and improves survival with immune checkpoint blockade in small cell lung cancer
Cancer Research·2025
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer
Molecular Cancer·2025· 5 citedOpen Access
Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents
JTO Clinical and Research Reports·2025· 3 citedOpen Access
Abstract A017: Identifying proliferative and immune-modulatory drivers of small cell lung cancer (SCLC)
Cancer Immunology Research·2024
MA17.11 NOTCH1 Expression Is Associated with Overall Survival in Small Cell Lung Cancer Patients Treated with Atezolizumab in IMpower133
Journal of Thoracic Oncology·2024· 1 citedOpen Access
Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Nature·2024· 3 citedOpen Access
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer
2024Open Access
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Nature·2024Open Access
Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC
Cancer Research·2024
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Nature·2024Open Access
Analytical evaluation of circulating tumor DNA sequencing assays
Scientific Reports·2024· 18 citedOpen Access
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Nature·2024· 103 citedOpen Access
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Cancer Cell·2024· 123 cited
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
Lung Cancer·2023· 41 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

John D. Minna(17), Adi F. Gazdar(11), Tony Mok(8), Ignacio I. Wistuba(8), Hartmut Koeppen(6), Mitsuo Sato(6), Wei Zou(5), John V. Heymach(5), Namrata S. Patil(5), Luc Girard(5), Lukas C. Amler(4), David Fabrizio(4), Peter M. Haverty(4), Robert Gentleman(4), Kenneth E. Huffman(4), Somasekar Seshagiri(4), Barzin Y. Nabet(4), Lauren A. Byers(4), Romain Banchereau(4), Melissa L. Johnson(3)